Long COVID vs Chronic Fatigue Syndrome: Key Differences
Quick Answer
Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) are not formally the same diagnosis, but research suggests they may share substantial biological overlap. Both conditions are classified as post-viral syndromes and are commonly associated with persistent fatigue, post-exertional malaise (PEM), cognitive dysfunction, immune dysregulation, mitochondrial impairment, and chronic inflammation. A subset of Long COVID patients may eventually meet ME/CFS diagnostic criteria (1-4).
At a Glance
- Long COVID and ME/CFS are distinct diagnoses that may share overlapping immune, metabolic, and neurological mechanisms.
- Post-exertional malaise (PEM) is considered a hallmark feature of ME/CFS and may also be present in a subset of Long COVID cases (16,17).
- Mitochondrial dysfunction and reduced ATP production have been documented in both conditions by researchers including Sarah Myhill and Bhupesh Prusty (7-9).
- Altered cytokine profiles and immune exhaustion markers, such as elevated interleukin-6 (IL-6) and tumour necrosis factor alpha (TNF-alpha), have been identified in both populations (10-12).
- Routine blood tests may appear normal despite measurable physiological dysfunction in energy metabolism and immune signalling (15).
- Functional medicine assessment may uncover root contributors that standard investigations miss, including gut dysbiosis, hormonal imbalance, and nutrient deficiencies.
Post-Viral Syndromes May Persist for Months or Years After Acute Infection
Post-viral syndromes describe a group of conditions in which symptoms persist for months or years after an acute infection has resolved. According to research by Andrew Lloyd and Ian Hickie at the University of New South Wales, common triggering infections include influenza, Epstein-Barr virus (EBV), Ross River virus, and SARS-CoV-2 (5,6).
Both Long COVID and ME/CFS are increasingly understood as systemic, multi-organ conditions rather than isolated organ diseases. The World Health Organization (WHO) published a clinical case definition for post COVID-19 condition in 2021, while the National Institute for Health and Care Excellence (NICE) updated its ME/CFS guidelines the same year (1,2). For a broader overview, see our guide on chronic fatigue.
Long COVID and ME/CFS Share At Least Three Key Biological Mechanisms
Mitochondrial Dysfunction
Impaired mitochondrial function may be present in both ME/CFS and Long COVID, leading to reduced adenosine triphosphate (ATP) generation and disproportionate fatigue following physical or cognitive exertion. Sarah Myhill and colleagues first documented this association in ME/CFS patients, finding correlations between mitochondrial test scores and symptom severity (7). Cara Tomas at Newcastle University confirmed impaired cellular bioenergetics in ME/CFS using extracellular flux analysis (8). More recently, Brent Appelman and colleagues at Amsterdam UMC demonstrated skeletal muscle mitochondrial dysfunction in Long COVID patients using muscle biopsy analysis published in Nature Metabolism (9).
Immune Dysregulation
In post-viral conditions, immune signalling may remain chronically activated or become functionally suppressed. Jose Montoya at Stanford University identified a distinct cytokine signature in ME/CFS patients, including altered levels of interleukin-6 (IL-6), interleukin-17A (IL-17A), and tumour necrosis factor alpha (TNF-alpha) (10). Chansavath Phetsouphanh and colleagues at the Kirby Institute demonstrated that immunological dysfunction, including T-cell exhaustion and elevated interferon-beta (IFN-beta), persists for at least eight months following SARS-CoV-2 infection (11). Jim Heath’s multi-omic study at the Institute for Systems Biology identified multiple early factors that may anticipate post-acute COVID-19 sequelae (12).
Persistent Inflammation
Low-grade, chronic inflammation has been documented across both conditions. Yasuhito Nakatomi and colleagues at Osaka City University used PET imaging to demonstrate widespread neuroinflammation in ME/CFS patients, with microglial activation in multiple brain regions (13). Daniel Albrecht’s research confirmed brain glial activation in post-viral fatigue states (14). Inflammatory signalling involving nuclear factor kappa B (NF-kB) and oxidative stress pathways may also interfere with mitochondrial efficiency and autonomic nervous system regulation, including effects on the gut microbiome.
Routine Blood Tests May Miss Functional Dysregulation in Both Conditions
Standard medical investigations, including full blood count, liver function tests, and thyroid-stimulating hormone (TSH), are designed to identify overt pathology rather than functional dysregulation. Robert Naviaux at the University of California San Diego proposed the cell danger response (CDR) model, suggesting that metabolic abnormalities in ME/CFS and Long COVID may involve purinergic signalling pathways not captured by routine panels (15).
Functional Medicine Assessment May Uncover Root Contributors
| Assessment Area | What Is Evaluated | Relevance to Post-Viral Conditions |
|---|---|---|
| Immune and inflammatory markers | High-sensitivity CRP, cytokine panels, NK cell function | May reveal ongoing immune activation or exhaustion not captured by standard tests |
| Gut microbiome analysis | Comprehensive stool testing for dysbiosis, permeability markers | Gut-immune axis dysfunction is associated with both ME/CFS and Long COVID |
| Hormonal evaluation | Thyroid panel (free T3, free T4, reverse T3), cortisol rhythm, DHEA | HPA axis dysregulation may contribute to fatigue and poor stress tolerance |
| Nutrient status testing | CoQ10, B vitamins, magnesium, zinc, vitamin D, iron studies | Nutrient deficiencies may impair mitochondrial function and immune recovery |
A Subset of Long COVID Patients May Eventually Meet ME/CFS Diagnostic Criteria
Not everyone with Long COVID will develop ME/CFS. However, Leonard Jason at DePaul University conducted longitudinal analysis showing that a subset of post-COVID individuals may later fulfil ME/CFS diagnostic criteria, particularly when post-exertional malaise is a dominant feature (16). Rosie Twomey and colleagues confirmed in a 2022 JAMA Network Open study that PEM is a significant predictor of functional disability in Long COVID patients (17).
| Feature | Long COVID | ME/CFS |
|---|---|---|
| Triggering pathogen | SARS-CoV-2 | EBV, influenza, enteroviruses, other viral/bacterial infections |
| Post-exertional malaise | Present in a subset | Required for diagnosis (NICE, IOM criteria) |
| Diagnostic criteria | WHO 2021 clinical case definition | Canadian Consensus Criteria, NICE NG206, IOM 2015 |
| Immune dysregulation | Documented (T-cell exhaustion, cytokine changes) | Documented (NK cell dysfunction, cytokine changes) |
| Mitochondrial involvement | Documented (Appelman et al., 2024) | Documented (Myhill et al., 2009; Tomas et al., 2017) |
| Neuroinflammation | Emerging evidence | PET-confirmed microglial activation (Nakatomi et al., 2014) |
Frequently Asked Questions
Key Insights
- Long COVID and ME/CFS share significant biological overlap involving immune, mitochondrial, and neuroinflammatory pathways
- Post-exertional malaise is a key distinguishing feature that may predict ME/CFS development in Long COVID patients
- Immune dysregulation and mitochondrial dysfunction are central mechanisms documented by multiple research groups
- Normal routine tests do not exclude meaningful physiological dysfunction in energy metabolism or immune signalling
Citable Takeaways
- Brent Appelman and colleagues demonstrated skeletal muscle mitochondrial dysfunction in Long COVID patients in a 2024 Nature Metabolism study, linking reduced oxidative phosphorylation to exercise intolerance (9).
- Jose Montoya’s Stanford research identified a cytokine signature involving 17 immune markers that correlated with ME/CFS severity, including elevated IL-6 and TNF-alpha (10).
- Yasuhito Nakatomi and colleagues at Osaka City University used PET imaging to confirm widespread neuroinflammation with microglial activation in ME/CFS patients across multiple brain regions (13).
- Chansavath Phetsouphanh’s Kirby Institute study found that T-cell exhaustion and elevated interferon-beta persist for at least eight months after SARS-CoV-2 infection, suggesting prolonged immune dysregulation in Long COVID (11).
- Leonard Jason’s longitudinal analysis at DePaul University found that a subset of post-COVID individuals may eventually meet ME/CFS diagnostic criteria, particularly when post-exertional malaise is present (16).
- Rosie Twomey’s 2022 JAMA Network Open study confirmed that post-exertional malaise is a significant predictor of functional disability in Long COVID patients, supporting pacing-based management approaches (17).
Struggling With Post-Viral Fatigue That Won’t Resolve?
If Long COVID or chronic fatigue symptoms are affecting your quality of life despite normal test results, a functional medicine approach may uncover what standard investigations miss. At Elemental Health and Nutrition, we investigate immune, metabolic, and gut health contributors to help you move forward.
References
- NICE. ME/CFS: diagnosis and management. NICE guideline NG206. 2021.
- WHO. A clinical case definition of post COVID-19 condition. 2021.
- Komaroff AL, Bateman L. Will COVID-19 lead to ME/CFS? Front Med. 2021;7:606824.
- Davis HE et al. Characterizing long COVID in an international cohort. EClinicalMedicine. 2021;38:101019.
- Hickie I et al. Post-infective and chronic fatigue syndromes. BMJ. 2006;333(7568):575.
- White PD et al. Predictors of persistent fatigue following viral infections. BMJ. 2001;323(7321):1132.
- Myhill S, et al. Chronic fatigue syndrome and mitochondrial dysfunction. Int J Clin Exp Med. 2009;2(1):1-16.
- Tomas C et al. Cellular bioenergetics is impaired in CFS patients. PLoS One. 2017;12(10):e0186802.
- Appelman B et al. Mitochondrial dysfunction in long COVID. Nat Metab. 2024;6(2):227-241.
- Montoya JG et al. Cytokine signature in ME/CFS. Proc Natl Acad Sci USA. 2017;114(39):E7150-E7158.
- Phetsouphanh C et al. Immunological dysfunction persists 8 months after SARS-CoV-2. Nat Immunol. 2022;23(2):210-216.
- Su Y et al. Multiple early factors anticipate post-acute COVID-19 sequelae. Cell. 2022;185(11):1875-1892.
- Nakatomi Y et al. Neuroinflammation in CFS patients. J Nucl Med. 2014;55(6):945-50.
- Albrecht DS et al. Brain glial activation in post-viral fatigue. Brain Behav Immun. 2019;79:158-165.
- Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014;16:7-17.
- Jason LA et al. A longitudinal analysis of ME/CFS diagnostic criteria. J Transl Med. 2021;19(1):222.
- Twomey R et al. Post-exertional malaise and disability in long COVID. JAMA Netw Open. 2022;5(7):e2222779.
